<DOC>
	<DOCNO>NCT02675153</DOCNO>
	<brief_summary>Crohn 's disease （CD） stenosis limit therapeutic option high surgical rate . The present clinical trial aim evaluate efficacy safety sirolimus treatment stricturing Crohn 's Disease .</brief_summary>
	<brief_title>To Evaluate Efficacy Safety Sirolimus Crohn 's Disease With Stenosis</brief_title>
	<detailed_description>Management Crohn 's disease （CD） stenosis challenge often require endoscopic dilatation surgical resection strictured bowel . Sirolimus ( rapamycin ) , macrocyclic antibiotic immunosuppressive antineoplastic property , report promising rescue therapy refractory CD . This study aim evaluate use sirolimus stricturing Crohn 's Disease . Patients study receive continuous dose schedule oral sirolimus 2mg daily six month follow-up least one year . The Harvey-Bradshaw Index （HBI） score , Blood test , MRI endoscopy use ass participant study start follow-up point .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>moderate severe Crohn 's Disease ( basic HBI ≥ 7 ) stenosis Allergic sirolimus serious side effect Need emergency surgery Accompanied severe disease ( involve C.diff infection ) Followup le 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>stenosis</keyword>
	<keyword>sirolimus</keyword>
	<keyword>rapamycin</keyword>
	<keyword>stricture</keyword>
</DOC>